Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease Dementia

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice